In the Matter of Efamol Nutraceuticals Inc. (2000) , File No. 992 3027

Efamol manufactured and distributed products that it claimed could treat ADHD in children. The FTC claimed that Efamol did not have any reliable scientific evidence to back up its claims.


Efamol claimed that two of its products could treat ADHD symptoms in children by managing fatty acid deficiencies. The FTC filed a complaint alleging that reliable scientific evidence did not exist that supported such a claim, in violation of the Federal Trade Commission Act. Efamol agreed to cease advertising that its products were effective at treating ADHD unless it could produce competent and reliable evidence that supported the company’s claim. In exchange for the voluntary cessation of the subject advertising, the FTC agreed to withdraw its complaint.

The full case and consent order is also available at:

LOADING PDF: If there are any problems, click here to download the file.

Published In: MLM / Direct Sales Updates, MLM Consulting / Network Marketing Updates

Reference Info:Federal, Federal Circuit | United States

Reporters on Deadline


Welcome to MLM Legal - a valuable resource to the Multi-Level Marketing and Direct Sales Industry. ... View Profile »

Follow Babener & Associates: